Suppr超能文献

多药耐药蛋白(MRP)过表达的人白血病细胞中多药耐药(MDR)的调节与谷胱甘肽之间的关系。

The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells.

作者信息

Grech K V, Davey R A, Davey M W

机构信息

Department of Cell and Molecular Biology, University of Technology, Sydney, Gore Hill NSW, Australia.

出版信息

Biochem Pharmacol. 1998 Apr 15;55(8):1283-9. doi: 10.1016/s0006-2952(97)00562-5.

Abstract

Multidrug resistance-associated protein (MRP) causes multidrug resistance (MDR) involving the anthracyclines and epipodophyllotoxins. Many studies show modulation of anthracycline levels and cytotoxicity in MRP-overexpressing cells, but there is limited data on the modulation of etoposide levels and cytotoxicity in MRP-overexpressing or in P-glycoprotein-expressing cells. Etoposide accumulation was 50% reduced in both the CEM/E1000 MRP-overexpressing subline and the CEM/VLB100 P-glycoprotein-expressing subline compared to the parental CEM cells, correlating with similar resistance to etoposide (200-fold) of the two sublines. For the CEM/VLB100 subline, the P-glycoprotein inhibitor SDZ PSC 833, but not verapamil, was able to increase etoposide accumulation and cytotoxicity. For the CEM/E1000 subline, neither SDZ PSC 833 nor verapamil had any effect on etoposide accumulation. However, verapamil caused a 4-fold sensitization to etoposide in this subline, along with an 80% decrease in cellular glutathione (P < 0.05). Buthionine sulfoximine (BSO), which depletes glutathione, also caused a 2.5-fold sensitization to etoposide with no effect on accumulation in the CEM/E1000 subline. In contrast, SDZ PSC 833 was able to increase daunorubicin accumulation in the CEM/E1000 subline (P < 0.05), but had no effect on daunorubicin cytotoxicity, or cellular glutathione. These results show that modulation of etoposide cytotoxicity in MRP-overexpressing cells may be through changes in glutathione metabolism rather than changes in accumulation and confirm that changes in drug accumulation are not related to drug resistance in MRP-overexpressing cells.

摘要

多药耐药相关蛋白(MRP)导致涉及蒽环类药物和表鬼臼毒素的多药耐药(MDR)。许多研究表明,在MRP过表达的细胞中,蒽环类药物水平和细胞毒性会受到调节,但关于在MRP过表达或P-糖蛋白表达的细胞中依托泊苷水平和细胞毒性调节的数据有限。与亲代CEM细胞相比,CEM/E1000 MRP过表达亚系和CEM/VLB100 P-糖蛋白表达亚系中的依托泊苷蓄积均减少了50%,这与两个亚系对依托泊苷的相似耐药性(200倍)相关。对于CEM/VLB100亚系,P-糖蛋白抑制剂SDZ PSC 833能够增加依托泊苷的蓄积和细胞毒性,而维拉帕米则不能。对于CEM/E1000亚系,SDZ PSC 833和维拉帕米对依托泊苷的蓄积均无任何影响。然而,维拉帕米使该亚系对依托泊苷的敏感性增加了4倍,同时细胞内谷胱甘肽减少了80%(P<0.05)。丁硫氨酸亚砜胺(BSO)可消耗谷胱甘肽,它也使CEM/E1000亚系对依托泊苷的敏感性增加了2.5倍,但对蓄积没有影响。相比之下,SDZ PSC 833能够增加CEM/E1000亚系中柔红霉素的蓄积(P<0.05),但对柔红霉素的细胞毒性或细胞内谷胱甘肽没有影响。这些结果表明,在MRP过表达的细胞中,依托泊苷细胞毒性的调节可能是通过谷胱甘肽代谢的变化而非蓄积的变化,并且证实药物蓄积的变化与MRP过表达细胞中的耐药性无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验